BMRN vs CPHI · P/E 40, rev $2.85B vs rev $4.1M
Biomarin Pharmaceutical Inc (BMRN) versus China Pharma Holdings Inc (CPHI) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
China Pharma Holdings Inc (CPHI) is a drug manufacturers - specialty & generic company listed on US.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported CPHI revenue for 2025-12-31 was $4.1M. Net income was -$3.2M. Revenue was down 8.5% from 2024-12-31 to 2025-12-31. CPHI currently screens at market cap $29.0M.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. CPHI currently screens at market cap $29.0M.
Not investment advice. Open the BMRN and CPHI stock pages for the full models.
Not investment advice.